Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
B. infantis 35624 vs B. longum 1714: B. infantis 35624 has the stronger overall evidence (5 vs 3/10); they work on different things and are often used together, not either/or. Take the 60-second quiz for a pick tailored to your goals.
B. infantis 35624 wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
1 x 10^8 CFU (100 million) daily — the dose that won the only head-to-head dose comparison; 1 x 10^10 CFU also beat placebo in a separate trial, so higher doses are not ruled out
any
Freeze-dried capsule standardized to 35624 at 1 x 10^8 CFU
1 x 10^9 to 1 x 10^10 CFU daily — the two trials that state a dose used 1 x 10^10 CFU/day (depression) and a minimum of 1 x 10^9 CFU/day (pregnancy). Neither found a benefit on its primary endpoint, so this is the dose range that has been tested, not a dose shown to work.
any
Freeze-dried capsule or sachet standardized to B. longum 1714
No interaction. The hazard is substitution — 1714 has no IBS trials at all, so the 35624 IBS evidence does not apply to it.
Listed for disambiguation rather than for stacking — no trial has combined them. Pick the strain matched to the outcome you want.
4 weeks
4 weeks
n/a
n/a
4 weeks
8 weeks
n/a
n/a
Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.
Am J Gastroenterol (2006) · Rct · n=362
1 x 10^8 CFU significantly superior to placebo AND to all other doses for the primary endpoint of abdominal pain
Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles.
Gastroenterology (2005) · Rct · n=77
Beat placebo on composite score and on abdominal pain, bloating/distention and bowel-movement difficulty for most treatment weeks
Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis.
Curr Med Res Opin (2017) · Meta analysis
Single-strain 35624 had no effect on abdominal pain, bloating/distention, or bowel-habit satisfaction
Effects of Bifidobacterium longum 1714 on low mood and related symptoms: A randomized, double-blind, placebo-controlled trial.
Exp Clin Psychopharmacol (2026) · Rct · n=168
PRIMARY ENDPOINT MISSED: BDI-II change vs placebo was -0.303 (95% CI -1.957 to 1.35, p=.718) at week 4 and -1.432 (95% CI -3.30 to 0.44, p=.132) at week 8
Bifidobacterium longum 1714 improves sleep quality and aspects of well-being in healthy adults: a randomized, double-blind, placebo-controlled clinical trial.
Sci Rep (2024) · Rct · n=89
PRIMARY ENDPOINT MISSED: PSQI global score improved in both groups, with no significant advantage for the strain
Bifidobacterium longum 1714 as a translational psychobiotic: modulation of stress, electrophysiology and neurocognition in healthy volunteers.
Transl Psychiatry (2016) · Pilot · n=22
PubMed classifies this as a Controlled Clinical Trial, NOT a Randomized Controlled Trial
B. infantis 35624 has a higher evidence score (5/10 vs 3/10) and wins in 2 of 3 categories.
No interaction. The hazard is substitution — 1714 has no IBS trials at all, so the 35624 IBS evidence does not apply to it. Listed for disambiguation rather than for stacking — no trial has combined them. Pick the strain matched to the outcome you want. Consult a healthcare provider for personalized advice.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.